THU0635\u2005REAL WORLD PHYSICIAN SATISFACTION WITH SECUKINUMAB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN EUROPE

Abstract

Background: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life. Secukinumab has demonstrated clinical benefits in PsA and AS, however little is known about physician satisfaction with its ability to control disease in the real world. Objectives: Assess physician satisfaction with secukinumab’s ability to control disease in a real-world setting. Methods: This was a cross-sectional survey of rheumatologists and dermatologists (PsA only) in France, Germany, Italy, Spain, and UK. Data were collected from Jun-Aug 2018 via physician-completed patient record forms. Patients receiving any treatment were included in the survey. Patients receiving secukinumab >1 month were included in this analysis. Physicians rated satisfaction on a 5-point scale (Very satisfied to very dissatisfied), a binary variable of satisfied/not satisfied was created by grouping “Very satisfied” and “Satisfied” responses as satisfied and “Neutral”, “Dissatisfied”, and “Very dissatisfied” as not satisfied. Data were reported by disease, then stratified by overall physician-rated disease severity (mild/moderate/severe) at initiation of secukinumab, prior biologic use, treatment duration, and concomitant medication. Results: 438 PsA and 277 AS patients were receiving secukinumab >1month at time of data collection. Patient mean age was 46.9 years (48.2 PsA, 44.8 AS) with 35.2% female (41.8% PsA; 24.9% AS). On average, patients had received secukinumab for 8.8 months (9.2 PsA; 8.2 AS). At secukinumab initiation, 44.2% of patients were rated by their physician as severe vs. 3.5% at the current consultation (39.3% vs. 2.7% PsA; 52.0% vs. 4.7% AS). Overall, 87.6% of physicians were satisfied with the ability of secukinumab to control disease (87.9% PsA; 86.3% AS). Physicians report high satisfaction across each stratification (Table 1).Table 1 Population characteristics, and physician reported satisfaction with secukinumab Population characteristics Satisfaction level N (%) PsA patients in each category (n=438) N (%) AS patients in each category (n=277) N (%) PsA physicians satisfied (n=438) N (%) AS physicians satisfied (n=277) Overall satisfaction - - 385 (87.9) 239 (86.3) Severity at initiation*MildModerateSevere 28 (6.4)236 (54.3)171 (39.3) 5 (1.8)128 (46.2)144 (52.0) 18 (64.3)210 (89.0)155 (90.6) 4 (80.0)109 (85.2)126 (87.5) Prior biologic useBio-experienced patientsBio-naive patients 191 (43.6)247 (56.4) 147 (53.1)130 (47.9) 155 (81.2)230 (93.1) 118 (80.3)121 (93.1) Secukinumab duration1-4 months>4-6 months>6 months 82 (18.7)120 (27.4)236 (53.9) 72 (26.0)68 (24.5)137 (49.5) 56 (68.3)108 (90.0)221 (93.6) 48 (66.7)61 (89.7)130 (94.9) Concomitant medicationMonotherapyCombination with a non-csDMARDCombination with a csDMARD 236 (53.9)104 (23.7)98 (22.4) 117 (42.2)113 (40.8)47 (17.0) 214 (90.7)89 (85.6)82 (83.7) 103 (88.0)95 (84.1)41 (87.2) *PsA base size=435 Conclusion: This study provides insight into physician satisfaction with secukinumab in a real-world clinical setting. Physicians reported being highly satisfied with the ability of secukinumab to control PsA and AS disease, regardless of patient population subgroups. Disclosure of Interests: Elizabeth Holdsworth Employee of: Adelphi Real World, Nicola Booth Employee of: Adelphi Real World, Steve Lobosco Employee of: Adelphi Real World, Olivia Massey Employee of: Adelphi Real World, Amie Scott Consultant for: Novartis Pharmaceuticals Corporation, Haijun Tian Shareholder of: Novartis Pharmaceutical Corporations, Employee of: Novartis Pharmaceutical Corporations, Dorothy Keininger Shareholder of: Novartis, Employee of: Novartis